Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Dove Medical Press full text link Dove Medical Press Free PMC article
Full text links

Actions

Share

.2018 Nov 13:12:2413-2424.
doi: 10.2147/PPA.S182563. eCollection 2018.

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine

Affiliations

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine

Janet H Ford et al. Patient Prefer Adherence..

Abstract

Background: Effects of galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, on patient satisfaction, health care resource utilization (HCRU), and acute medication use were evaluated in a long-term, open-label study in patients with migraine.

Methods: Patients with episodic (78.9%) or chronic migraine (21.1%) were evaluated in the CGAJ study, an open-label study with 12-month treatment period. Galcanezumab 120 mg (with a loading dose of 240 mg) or 240 mg was administered subcutaneously once a month during treatment period. A self-rated scale, Patient Satisfaction with Medication Questionnaire-Modified (PSMQ-M), was used to measure satisfaction levels. Participants reported HCRU for the previous 6 months at baseline and that which occurred since the patient's last study visit during treatment period. Acute headache medication use for migraine or headache for the past month was self-reported by participants at baseline and at each monthly visit during treatment period.

Results: At Months 1, 6, and 12, at least 69% of patients treated with galcanezumab responded positively for overall satisfaction, preference over prior treatments, and less impact from side effects. There were within-group reductions from baseline in migraine-specific HCRU (per 100 person-years) with galcanezumab for health care professional visits (173.4 to 59.6), emergency room visits (20.2 to 4.7), and hospital admissions (3.7 to 0.4) during treatment period. Statistically significant reductions in HCRU were observed for some events. There were significant within-group reductions from baseline in mean number of days/month with acute headache medication use for migraine or headache at each monthly visit during treatment period (overall change: -5.1 for galcanezumab 120 mg/240 mg;p<0.001).

Conclusion: Results from this long-term, open-label study suggest that treatment with galcanezumab is likely to lead to high patient satisfaction with treatment as well as meaningful reductions in migraine-specific HCRU and acute headache medication use in people with migraine.

Keywords: HCRU; acute medication; galcanezumab; migraine; open-label; satisfaction.

PubMed Disclaimer

Conflict of interest statement

Disclosure JHF, SAF, VLS, DDR, and SKA are full-time employees of Eli Lilly and Company and/or one of its subsidiaries and may hold company stocks. JV received personal fees and nonfinancial support from Teva, personal fees from Novartis, and grants and nonfinancial support from Allergan. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study design of Study CGAJ.Notes:aPatients randomized to the 120 mg dose will receive a loading dose of 240 mg at the first injection only (Visit 2).bTelephone visit.Abbreviation: SP, study period.
Figure 2
Figure 2
Reduction in number of migraine headache days per month in patients with episodic migraine (A) and chronic migraine (B).Notes: Results are LS mean change from baseline ± SE.^p<0.001;**p<0.01.Abbreviations: GMB, galcanezumab; LS, least square; SE, standard error.
Figure 3
Figure 3
Migraine-specific HCRU as count of persons with at least one visit (%) (A), and as per 100 patient-years (B) during baseline period and treatment period.Notes:^p<0.0001,*p<0.01 for within-group differences from baseline. More statistical comparisons were not performed for the analysis in (A) and for the GMB all group in (B).Abbreviations: ER, emergency room; GMB, galcanezumab; HCP, health care professional.
Figure 4
Figure 4
Change from baseline in number of days per month with acute medication use for migraine or headache. Changes at each month (A) and overall change (B) from baseline are shown.Notes: Results are LS mean change ± SE from baseline. Significant within-group differences were noted in both the GMB dose groups at each month and overall,^p<0.001.Abbreviations: GMB, galcanezumab; SE, standard error; LS, least squares.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dodick DW. Migraine. Lancet. 2018;391(10127):1315–1330. - PubMed
    1. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl 2):103–122. quiz 123–126. - PubMed
    1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edn. Cephalalgia. 2018;38(1):1–211. - PubMed
    1. Merikangas KR. Contributions of epidemiology to our understanding of migraine. Headache. 2013;53(2):230–246. - PubMed
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602. - PMC - PubMed

Related information

LinkOut - more resources

Full text links
Dove Medical Press full text link Dove Medical Press Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp